PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA IEC | PubSys CalAccessCommittee header
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA IEC
Active cycles
2003-20042005-20062007-20082009-20102011-20122013-20142015-20162017-20182019-20202021-20222023-20242025-2026
Panel 2 • Finance overview
Committee finance snapshot
Scope: 2025-2026 cycle
- Raised
- $1,867,590Dated receipts + reported unitemized intervals
- Spent
- $1,613,782
- Net activity
- $253,808
Receipt coverage evidence (23 components)
- Filing 3037149, amendment 0, F497P2: Receipt date 2025-04-24; $125,000.00; s497_not_received
- Filing 3094417, amendment 0, F497P2: Receipt date 2025-11-19; $10,000.00; s497_not_received
- Filing 3130654, amendment 0, F497P2: Receipt date 2026-04-02; $12,500.00; s497_not_received
- Filing 3151847, amendment 0, F497P2: Receipt date 2026-05-12; $50,000.00; s497_not_received
- Filing 3157718, amendment 0, F497P2: Receipt date 2026-05-21; $26,500.00; s497_not_received
- Filing 3189342, amendment 0, F497P2: Receipt date 2026-08-25; $50,000.00; s497_not_received
- Filing 3189342, amendment 0, F497P2: Receipt date 2026-08-25; $25,000.00; s497_not_received
- Filing 3058009, amendment 0, F460: 2025-01-01 – 2025-06-30; amount unknown; accepted · whole interval in window
- Filing 3105186, amendment 0, F460: 2025-07-01 – 2025-12-31; amount unknown; accepted · whole interval in window
- Filing 3137312, amendment 0, F460: 2026-01-01 – 2026-04-18; amount unknown; accepted · whole interval in window
- Filing 3155340, amendment 0, F460: 2026-04-19 – 2026-05-16; amount unknown; accepted · whole interval in window
- Filing 3174210, amendment 0, F460: 2026-05-17 – 2026-06-30; amount unknown; accepted · whole interval in window
Panel 3 • Money structure snapshot
Money structure snapshot
$5,000+ is the largest bucket at 99.9% of dated attributable receipts.
Dominant category: Operations at 96% of spending.
Funding distribution
$5,000+
Count: 29
Share: 99.9%
Amount: $1,865,600
$100 - $499
Count: 10
Share: 0.1%
Amount: $1,990
Panel 5 • Financial evidence
Filings workspace
Filing history and transaction-level evidence moved to a dedicated page.
Open filings pageLarge-donor funded, Non-media-led spender, Active in 2025-2026 cycle.
Money over time
Dated receipts only; unitemized reporting intervals are not allocated to dates.
ContributionsExpenditures
Jan 2025Aug 2025Feb 2026Sep 2026
| $5,000+ | 29 | $1,865,600 | 99.9% |
| $100 - $499 | 10 | $1,990 | 0.1% |
Spending categories
Operations
Amount: $1,548,787
Share: 96%
Consulting
| Category | Amount | Share of spent |
|---|
| Operations | $1,548,787 | 96% |
| Consulting | $64,995 | 4% |
Panel 4 • Top donors
Top donors
| Donor | Total | Share* | Count | Last |
|---|
| AMGEN, INC. | $130,400 | 7% | 2 | Feb 17, 2026 |
| BAYER US, LLC(DEVON ANDERSON) | $130,400 | 7% | 2 | Feb 17, 2026 |
| BRISTOL-MYERS SQUIBB COMPANY | $130,400 | 7% | 2 | May 7, 2026 |
| ELI LILLY AND COMPANY | $130,400 | 7% | 2 | May 7, 2026 |
| GENENTECH, INC. | $130,400 | 7% | 2 | May 7, 2026 |
| MERCK & CO. INC | $130,400 | 7% | 2 | Mar 10, 2026 |
| NEUROCRINE BIOSCIENCES | $130,400 | 7% | 2 | May 7, 2026 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $130,400 | 7% | 2 | May 7, 2026 |
| OTSUKA | $130,400 | 7% | 2 | Feb 17, 2026 |
| SANOFI-AVENTIS | $130,400 | 7% | 2 | Mar 10, 2026 |
| UCB, INC. | $130,400 | 7% | 2 | Mar 10, 2026 |
| GLAXOSMITHKLINE (GSK) | $65,200 | 3.5% | 1 | Mar 10, 2026 |
| GSK | $65,200 | 3.5% | 1 | May 14, 2025 |
| LUNDBECK INC. | $65,200 | 3.5% | 1 | Apr 14, 2025 |
| LUNDBECK, INC. | $65,200 | 3.5% | 1 | Feb 17, 2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC. | $65,200 | 3.5% | 1 | May 14, 2025 |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | $65,200 | 3.5% | 1 | Mar 10, 2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $40,000 | 2.1% | 1 | Dec 18, 2025 |
| BIOGEN INC. | $398 | 0% | 2 | Aug 4, 2026 |
| EISAI, INC. | $398 | 0% | 2 | Feb 17, 2026 |
| GENMAB | $398 | 0% | 2 | Mar 10, 2026 |
| ALKERMES, INC. | $199 | 0% | 1 | Apr 14, 2025 |
| ASTRAZENECA PHARMACEUTICALS | $199 | 0% | 1 | Mar 10, 2026 |
| IPSEN BIOPHARMACEUTICALS, INC. | $199 | 0% | 1 | Feb 17, 2026 |
| ISPEN BIOPHARMACEUTICALS | $199 | 0% | 1 | Mar 11, 2025 |
* Share is percent of committee total raised in the selected scope. Page rows are a subset and typically do not sum to 100%.